2006-07 Swaziland Demographic and Health Survey
General fact sheet in booklet form about the 2014-2015 Demographic and Health Survey conducted in Rwanda. The 2010 Rwanda Demographic and Health Survey (RDHS) provides up-to-date information on the population and health situation in Rwanda. The 2010 RDHS is the fifth national Demographic and Health ...Survey conducted in the country. Repeated surveys allow for an analysis of trends over time. The survey is based on a nationally representative sample. It provides estimates at the national and provincial levels.
more
Nigeria is Africa’s most populous nation and accounts for nearly one quarter of the continent’s maternal, newborn and child deaths. In the spirit of the global Countdown to 2015 for Maternal, Newborn and Child Health and the Nigerian Saving One Million Lives Initiative, these state data profiles... have been designed to prompt and inform policy and programme action.
Without data there can be no accountability. Without accountability we risk making no progress for Nigeria’s women and children. The data included in these profiles come mainly from large-scale, periodic household surveys. Continued efforts are needed to strengthen civil registration, vital statistics and health management information systems, as well as the institutional capacity to gather and use these data.
Updated from 2011, these data profiles can be used to compare progress in different areas, identify opportunities to address specific coverage gaps, and monitor implementation.
more
Este informe presenta los resultados obtenidos de la evaluación de la efectividad de las vacunas contra la COVID-19 en Chile utilizando la red de vigilancia centinela de infecciones respiratorias agudas graves (IRAG). Los resultados que se presentan en este informe provienen de los datos proporcion...ados por esta red para el periodo de enero a diciembre de 2021.
more
En Paraguay, la vacunación contra COVID-19 inició el 22 de febrero de 2021. Se han autorizado un total de siete vacunas: Bharat-Covaxin, Moderna, Pfizer-BioNTech, AstraZeneca, Sinopharm, Sputnik V- Gamaleya y CoronaVac-Sinovac. Los grupos prioritarios de vacunación están definidos según el Plan... Nacional de Vacunación contra COVID-19 en Paraguay
more
La evidencia disponible a nivel internacional sobre el uso de un segundo refuerzo muestra una mayor duración de la respuesta inmune y una disminución de la internación y la mortalidad por COVID 19 en la población de adultos mayores y huéspedes inmunocomprometidos. Por otra parte, el personal de... salud se beneficiaría considerando el mayor riesgo de exposición y la caída de la respuesta inmune con el tiempo. En base a lo señalado previamente se recomienda incorporar y
priorizar un segundo refuerzo al esquema de vacunación contra la COVID-19 del:
- Personal de salud independientemente de la edad
- Personas de 50 años o mayores
- Personas de 12 años o más con inmunocompromiso
A la vez, se progresará de manera escalonada y simultánea con la vacunación de segundo refuerzo del:
- Personal estratégico
- Personas de 18 a 49 años con factores de riesgo
Continuando en la estrategia de segundo refuerzo todas las personas a partir de los 18 años. Las personas gestantes con indicación de segundo refuerzo, se recomienda vacunas de plataforma de ARNm (Pfizer-BioNTech o Moderna)
more
Los datos preliminares de eficacia se infirieron mediante un enfoque de “inmunogenicidad puente”, en el que los títulos neutralizantes obtenidos después de la vacuna en niños y niñas de 5 a 11 años se compararon con los títulos obtenidos en adolescentes de 16 a 25 años (en quienes se hab...a evaluado la eficacia).Entre los participantes sin evidencia de infección previa por SARS-CoV-2, hubo 3 casos de COVID-19 entre los 1.305 receptores de vacuna a partir de los 7 días de la segunda dosis y 16 entre los 663 receptores de placebo.
more
El siguiente manual se continuará actualizando, de ser necesario, a medida que se disponga de nueva información.
To survive and thrive from early childhood through to adolescence and beyond, children need to be healthy. This enables them to access education so that every child in Ukraine, irrespective of background or circumstance, has an equal chance to fulfill their potential.
To ensure children thrive and ...remain in good health, the United Nations Children's Fund (UNICEF) has delivered to Ukraine 700,000 doses of tetanus-diphtheria (Td) vaccine to protect children after six and adults.
more
Дитячий фонд ООН (ЮНІСЕФ) доставив в Україну понад 700 тис. доз вакцини для профілактики дифтерії та правця зі зменшеним вмістом антигена (АДП-М), яку використовують д...ля дітей після 6 років та дорослих.
Вакцини будуть розподілені по Україні відповідно до потреб, визначених Міністерством охорони здоров’я.
more
Classical rabies caused by RABV occurs worldwide besides some isolated countries and Western Europe that are regarded rabies free. Carnivores, especially of the canidae family represent the principal reservoir species and are responsible for the maintenance of the infectious cycle and hence for the ...presence of the disease (see Epidemiology of rabies). While wildlife rabies maintained by different reservoirs hosts predominantly occurs in the Northern hemisphere, canine rabies is by far more important for public health in the developing world.
more
Video
Further OIE Support for African Countries on Rabies vaccines
Chikungunya fever (CHIKF) is an emerging infectious disease caused by an alphavirus transmitted by Aedes spp. mosquitoes. Because mosquito control programs are not highly efficient for outbreak containment, vaccines are essential to reduce the burden of disease. Although no licensed vaccine against ...CHIKF is yet available, many highly promising candidates are undergoing preclinical studies, and a few of them have been tested in human trials of phase 1 or 2. Here, we review recent findings regarding the need for a CHIKF vaccine and provide an update on vaccines nearing or having entered clinical trials. We also address needs to tackle bottlenecks to vaccine development—including scientific and financial barriers—and to accelerate the development of vaccines; several actions should be taken:
(i) design efficacy trials to be conducted during the course of outbreaks;
(ii) evaluate the opportunity for adopting the “animal rule”for demonstration of efficacy for regulatory purposes;
(iii) strengthen the collective commitment of nations, international organizations, potential donors and industry;
(iv) stimulate public and/or private partnerships to invest in vaccine development and licensure; and
(v) identify potential markets for an effective and safe CHIKF vaccine.
more
Dengue Vaccines: Current Status and Future Prospects
Website last accessed on 22.05.2023
Leishmaniasis refers to a diverse group of diseases caused by single-celled parasites called Leishmania. About 12 million people are infected at any one time, causing up to 40,000 deaths annually.
The VALIDATE Network - Vaccine development for complex intra...cellular neglected pathogens
more